Merck's Cancidas and Astellas's Mycamine Cut Prices, According To New Data
from Arlington Medical Resources
MALVERN, Penn., Oct. 30 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that echinocandins show growth in the share of courses among all antifungal classes: 10.7 percent of all courses in the January - June 2008 time period compared to 9 percent in the January - June 2007 time period. Echinocandins are a class of antifungal agents consisting of Merck's Cancidas (caspofungin), Astellas's Mycamine (micafungin) and Pfizer's Eraxis (anidulafungin). These agents are commonly used to treat lung tissue infections, disseminated fungal infection and fungemia and are administered intravenously.
"Cancidas currently enjoys the largest share of courses within the echinocandin class (66 percent), followed by Mycamine (22 percent) and Eraxis (13 percent)," stated Joyce Wedemeyer, product director at AMR. "However, Cancidas's share decreased from the previous time period from 74 percent, Mycamine's increased from 13 percent and Eraxis's remained the same at 13 percent."
The newly released U.S. edition of The Hospital Antifungal Market Guide also finds that Cancidas and Mycamine have cut their prices. This cost information is based on hospital acquisition cost.
"Cancidas and Mycamine have both decreased in the average cost/day (in U.S. dollars). Cancidas's average cost/day decreased 12 percent from $174 to $152 and Mycamine's average cost/day decreased 4 percent from $137 to $131," added Ms. Wedemeyer. "However, Eraxis's -the newest of these drugs-average cost/day remained stable at $165."
Why Pharmaceutical Companies Need this Information
The Hospital Antifungal Market Guide enables pharmaceutical companies to monitor inpatient shares, costs and the clinical use of systemic antifungal agents. For every therapeutic drug course there is a link between drug, diagnosis and suspected or confirmed fungal pathogen.
About The Hospital Antifungal Market Guide
The Hospital Antifungal Market Guide is the industry's most comprehensive audit of hospital systemic antifungal drug usage covering acute care hospitals in the United States, Italy, Germany, France, U.K. and Spain. The information in the audit is abstracted directly from hospital source documents from a panel of demographically representative acute care hospitals of all sizes, including transplant centers. The U.S. data is published twice a year and the European data is published once a year.
AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that
offers best-in-class, high-value information and insights on important
sectors of the healthcare industry. Clients rely on this analysis and data
to make informed decisions. Please visit Decision Resources, Inc. at
All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Natalia Morales Elizabeth Marshall
Decision Resources Decision Resources, Inc.
|SOURCE Arlington Medical Resources|
Copyright©2008 PR Newswire.
All rights reserved